Innate immunity-modulating nanobiomaterials for controlling inflammation resolution
Matter · 2024-11 · 7 (11) · 3811-3844
DOI: 10.1016/j.matt.2024.09.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Matter, 2024-11. Verfasst von Yongjiang Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Bost…. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 254 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
The acute inflammatory response is an inherent protective mechanism, its unsuccessful resolution can contribute to disease pathogenesis and potentially lead to death. Innate immune cells are the first line of host defenders and play a substantial role in inflammation initiation, amplification, resolution, or subsequent disease progression. As the resolution of inflammation is an active and highly regulated process, modulating innate immune cells, including neutrophils, monocytes and macrophages, and endothelial cells, and their interactions offer opportunities to control excessive inflammation. Nanobiomaterials have shown superior therapeutic potential in inflammation-related diseases by manipulating inflammatory responses because nanobiomaterials can target and interact with innate immune cells. Versatile nanobiomaterials can be designed for targeted modulation of specific innate immune responses. Nanopro-resolving medicines have been prepared both with pro-resolving lipid mediators and peptides each demonstrated to active resolution of inflammation in animal disease models. Here, we review innovative nanobiomaterials for modulating innate immunity and alleviating inflammation. We summarise the strategies converging the design of nanobiomaterials and the nano-bio interaction in modulating innate immune profiles and propelling the advancement of nanobiomaterials for inflammatory disease treatments. We also propose the future perspectives and translational challenges of nanobiomaterials that need to be overcome in this swiftly rising field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- These authors contributed equally: Yongjiang Li, Wei Chen.
- Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 17177, Sweden.
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- American Society of Transplantation
- American Heart Association Inc
- National Institute of Allergy and Infectious Diseases
- Novo Nordisk
- National Institute of Health
Zitieren
APA
Li, Y., Chen, W., Koo, S., Liu, H., Saiding, Q., Xie, A., Kong, N., Cao, Y., Abdi, R., Serhan, C. N., & Tao, W. (2024). Innate immunity-modulating nanobiomaterials for controlling inflammation resolution. Matter, 7(11), 3811-3844. https://doi.org/10.1016/j.matt.2024.09.016
Vancouver
Li Y, Chen W, Koo S, Liu H, Saiding Q, Xie A, et al. Innate immunity-modulating nanobiomaterials for controlling inflammation resolution. Matter. 2024;7(11):3811-3844. doi:10.1016/j.matt.2024.09.016
BibTeX
@article{Li2024,
author = {Li, Yongjiang and Chen, Wei and Koo, Seyoung and Liu, Haijun and Saiding, Qimanguli and Xie, Angel and Kong, Na and Cao, Yihai and Abdi, Reza and Serhan, Charles N and Tao, Wei},
title = {Innate immunity-modulating nanobiomaterials for controlling inflammation resolution},
journal = {Matter},
year = {2024},
volume = {7},
number = {11},
pages = {3811--3844},
doi = {10.1016/j.matt.2024.09.016}
}
EUVIMED